Joseph G. Phillips

Dr. Joseph Phillips joined ArmaGen in May 2017. In his 27 years of leadership experience in the biopharmaceutical industry he has managed organizations engaged in drug substance and drug product manufacturing process development serving R&D and manufacturing operations.

He led advanced work in genomics, proteomics and metabolomics technologies to understand how cell culture media constituents, bioprocess raw materials and processing conditions impact product quality attributes and productivity to improve prediction of manufacturing results. He pursued the use of high resolution analytical techniques to measure human biological transformation and physiological clearance of drug product variants to assign critical product quality attributes.

Prior to joining ArmaGen, Joseph was a biotechnology consultant to biopharmaceutical executive leaders for bioprocess & product development CMC, manufacturability, QbD, cGMP and technical operations.

Before his consultancy, Joseph held several Executive Director positions at Amgen delivering successful global CMC regulatory submissions for Neulasta, Aranesp, Sensipar/Mimpara, Enbrel, Vectibix, Prolia, XGEVA and Repatha. Prior to Amgen, he served in several leadership roles at GlaxoSmithKline. He started his career in the biopharmaceutical industry at Upjohn (acquired by Pharmacia/Pfizer). Joseph received his Ph.D. in pharmaceutics and analytical chemistry from Brighton University (UK), his M.Sc. in organometallic chemistry from University of Sussex (UK) and his B.Sc. in applied chemistry from Brighton University (UK).